WEGOVY® 2.4mg is the maintenance dose in the semaglutide-based weight management protocol. It helps sustain long-term weight loss results after the patient has completed the dose-escalation phase, providing appetite regulation and improved metabolic outcomes.
- Active ingredient: Semaglutide 2.4mg per 0.5 mL
- Form: Single-use FlexTouch® pen (pre-filled)
- Dosing frequency: Once weekly
- Therapeutic class: GLP-1 receptor agonist
- Used after titration: Reached in week 17 of treatment
- Color-coded: Green packaging for 2.4mg dose
- Target outcome: Long-term weight reduction and maintenance
WEGOVY® FLEXTOUCH® 2.4mg – Unique Technology
The FlexTouch® delivery system is designed to support ease of use, precision, and safety for patients self-administering semaglutide. Its pre-set dosing, automatic needle retraction, and visual feedback make it ideal for long-term adherence.
- No dose adjustment: Pen delivers exact 2.4mg dose
- Automatic needle retraction: Improves user safety and comfort
- Visual indicator: Yellow bar confirms full dose delivery
- Hidden needle: Reduces injection-related anxiety
- Compatible with NovoFine® Plus needles
- Ergonomic design supports use by patients with limited dexterity
WEGOVY® FLEXTOUCH® 2.4mg – Indications
WEGOVY® 2.4mg is indicated for chronic weight management in adults with obesity or overweight plus at least one weight-related condition. It should always be used in combination with lifestyle interventions.
- Adults with BMI ≥30 kg/m²
- Adults with BMI ≥27 kg/m² with comorbidities such as:
- Type 2 diabetes
- Dyslipidemia
- Hypertension
- Obstructive sleep apnea
- Not indicated for:
- Children and adolescents (<18 years)
- Pregnancy or breastfeeding
WEGOVY® FLEXTOUCH® 2.4mg – Dosage and Administration
After a 16-week escalation protocol, patients continue on the 2.4mg maintenance dose indefinitely, depending on clinical response and tolerance. It is injected subcutaneously once weekly.
- Week 17+ dose in the escalation plan:
- Week 1–4: 0.25 mg
- Week 5–8: 0.5 mg
- Week 9–12: 1.0 mg
- Week 13–16: 1.7 mg
- Week 17+: 2.4 mg
- Injected into abdomen, thigh, or upper arm
- Must be administered on the same day each week
- Can be taken with or without food
- If missed dose <5 days: take immediately
- If missed dose >5 days: skip and wait for next scheduled day
WEGOVY® FLEXTOUCH® 2.4mg – Side Effects and Precautions
The 2.4mg dose is associated with dose-dependent gastrointestinal effects. Most side effects occur during the titration phase but can persist, especially in sensitive individuals.
- Very common (≥1/10):
- Nausea, vomiting, diarrhea, constipation
- Abdominal pain, fatigue, headache
- Common (≥1/100 to <1/10):
- Injection site reactions
- Gastroesophageal reflux
- Hair loss, dizziness
- Uncommon/Rare:
- Acute pancreatitis
- Gallbladder disease (e.g., cholelithiasis)
- Kidney injury secondary to dehydration
- Suicidal ideation (monitor in at-risk patients)
- Contraindications:
- Personal/family history of MTC
- MEN 2 syndrome
- Known hypersensitivity to semaglutide or excipients
WEGOVY® FLEXTOUCH® 2.4mg – Clinical Studies and Real-World Outcomes
WEGOVY® 2.4mg was shown to deliver consistent and sustained weight loss in multiple Phase 3 clinical trials (STEP program). Patients maintained reductions in body weight and improvements in cardiometabolic risk markers.
- STEP 1 trial: Average weight loss of ~15% over 68 weeks
- Improved HbA1c, blood pressure, and cholesterol levels
- Majority of patients maintained ≥5–10% weight loss at maintenance dose
- Higher dose yielded better satiety, reduced food cravings
- Demonstrated cardiovascular safety and metabolic improvement
WEGOVY® FLEXTOUCH® 2.4mg – Drug Interactions
Semaglutide slows gastric emptying, which may affect the absorption and timing of certain oral medications. Interaction risk increases with antidiabetics and medications with a narrow therapeutic range.
- May increase hypoglycemia risk with:
- Insulin
- Sulfonylureas
- Monitor use with:
- Oral contraceptives
- Levothyroxine
- Cardiovascular drugs (e.g., beta blockers)
- Should not be co-administered with other GLP-1 agonists
- Discuss any vitamins, supplements, or herbal products with physician
WEGOVY® FLEXTOUCH® 2.4mg – Post-Treatment Care
After discontinuation, patients may experience a return in appetite and regain weight if lifestyle interventions are not sustained. Ongoing care and monitoring are essential for long-term outcomes.
- Reinforce healthy eating and exercise habits
- Monitor for weight regain or cardiometabolic relapse
- Reassessment needed if weight returns or side effects persist
- Dispose of used pens in a sharps container
- Women must notify provider if planning pregnancy
- Evaluate thyroid function and any signs of thyroid swelling or hoarseness